Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Thomas F. Gajewski, Juan Martín-Liberal et al.|Nature|2024Cited by 107
Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.Elisa Fontana, Ramy Saleh, Aakash Desai et al.|Journal of Clinical Oncology|2025Cited by 2